What Happened?
Cambridge, MA-based Sage Therapeutics Appointed Shelly Adler as Director, Benefits
About the Company
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
About the Person
Shelly Adler is Director, Benefits at ImmunoGen. Previously, Shelly held various senior HR leadership roles in the industry.
Info Source
News
Short Profile